Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the t
Provided herein are tetrazolone FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, RB and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.
대표청구항▼
1. A compound of formula (I): or a pharmaceutically acceptable form thereof; wherein: RA is selected from C6-14 aryl and 5-14 membered heteroaryl;RB is selected from C6-14 aryl and 5-14 membered heteroaryl, wherein RB is substituted at least with the group -L-RD;RC is selected from C1-10 alkyl, C1-1
1. A compound of formula (I): or a pharmaceutically acceptable form thereof; wherein: RA is selected from C6-14 aryl and 5-14 membered heteroaryl;RB is selected from C6-14 aryl and 5-14 membered heteroaryl, wherein RB is substituted at least with the group -L-RD;RC is selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, with the proviso that RC is not —CH3;wherein:L is a covalent bond or a divalent C1-10 hydrocarbon chain, wherein one, two or three methylene units of L are optionally and independently replaced with one or more —O—, —S—, —NRB8—, —(C═NRB8)—, —C(═O)—, —C(═S)—, —S(═O)—, —S(═O)2—, divalent carbocyclyl, divalent heterocyclyl, divalent aryl or divalent heteroaryl group;RD is selected from N3, —SO2H, —SO3H, —C(═O)RB7, —CO2H, —CHO, —C(ORB9)2, —CO2RB7, —OC(═O)RB7, —OCO2RB7, —C(═O)N(RB8)2, —OC(═O)N(RB8)2, —NRB8C(═O)RB7, —NRB8CO2RB7, —NRB8C(═O)N(RB8)2, —C(═NRB8)ORB7, —OC(═NRB8)RB7, —OC(═NRB8)ORB7, —C(═NRB8)N(RB8)2, —OC(═NRB8)N(RB8)2, —NRB8C(NRB8)N(RB8)2, —C(═O)NRB8SO2RB7, —NRB8SO2RB7, —SO2N(RB8)2, —SO2RB7, —SO2ORB7, —OSO2RB7, —S(═O)RB7, —OS(═O)RB7—C(═S)N(RB8)2, —C(═O)SRB7, —C(═S)SRB7, —SC(═S)SRB7, —P(═O)2RB7, —OP(═O)2RB7, —P(═O)(RB7)2, —OP(═O)(RB7)2, —OP(═O)(ORB9)2, —P(═O)2N(RB8)2, —OP(═O)2N(RB8)2, —P(═O)(NRB8)2, —OP(═O)(NRB8)2, —NRB8P(O)(ORB9)2, NRB8P(═O)(NRB8)2, —B(ORB9)2, —BRB7(ORB9), and tetrazolyl;each instance of RB7 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each instance of RB8 is, independently, selected from hydrogen, —OH, —ORB7, —N(RB9)2, —CN, —C(═O)RB7, —C(═O)N(RB9)2, —CO2RB7, —SO2RB7, —C(═NRB9)ORB7, —C(═NRB9)N(RB9)2, —SO2N(RB9)2, —SO2RB9, —SO2ORB9, —SORB7, —C(═S)N(RB9)2, —C(═O)SRB9, —C(═S)SRB9, —P(═O)2RB7, —P(═O)(RB7)2, —P(═O)2N(RB9)2, —P(═O)(NRB9)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB8 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; andeach instance of RB9 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB9 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring. 2. The compound of claim 1, wherein L is a covalent bond. 3. The compound of claim 1, wherein L is a divalent C1-10 hydrocarbon chain, wherein one methylene unit of L is optionally and independently replaced with a divalent carbocyclyl, divalent heterocyclyl, divalent aryl or divalent heteroaryl group. 4. The compound of claim 1, wherein RD is selected from —SO2H, —SO3H, —C(═O)RB7, —CO2H, —CHO, —CO2RB7, —C(═O)N(RB8)2, —C(═NRB8)ORB7, —C(═NRB8)N(RB8)2, —C(═O)NRB8SO2RB7, —SO2N(RB8)2, —SO2RB7, —SO2ORB7, —S(═O)RB7, —C(═S)N(RB8)2, —C(═O)SRB7, —C(═S)SRB7, —P(═O)2RB7, —P(═O)(RB7)2, —P(═O)2N(RB8)2, —P(═O)(NRB8)2, —B(ORB9)2, —BRB7(ORB9) and tetrazolyl. 5. The compound of claim 4, wherein RD is selected from —C(═O)RB7, —CO2H, —CHO, —CO2RB7, —C(═O)N(RB8)2, —C(═NRB8)ORB7, —C(═NRB8)N(RB8)2, —C(═O)NRB8SO2RB7, —C(═S)N(RB8)2, —C(═O)SRB7 and —C(═S)SRB7. 6. The compound of claim 5, wherein RD is selected from —C(═O)RB7, —CO2H, —CHO, and —CO2RB7. 7. The compound of claim 6, wherein RD is —CO2H. 8. The compound of claim 1, wherein RB is further substituted with the group: —RE wherein:RE is selected from halogen, —OH, —ORB10, —ON(RB11)2, —N(RB11)2, —N(ORB12)RB12, —SH, —SRB10, —SSRB12, —OC(═O)RB10, —OCO2RB10, —OC(═O)N(RB11)2, —NRB11C(═O)RB10, —NRB11CO2RB10, —NRB11C(═O)N(RB11)2, —OC(═NRB11)RB10, —OC(═NRB11)ORB10, —OC(═NRB11)N(RB11)2, —NRB11C(═NRB11)N(RB11)2, —NRB11SO2RB10, OSO2RB10, —OS(═O)RB10, —Si(RB10)3, —OSi(RB10)3, —SC(S)SRB10, —OP(═O)2RB10, —OP(═O)(RB10)2, —OP(═O)(ORB12)2, —OP(═O)2N(RB11)2, —OP(═O)(NRB11)2, —NRB11P(═O)(ORB12)2, —NRB11)2, —P(RB12)2, —P(RB12)3, —OP(RB12)2, —OP(RB12)3, 3-14 membered heterocyclyl and 5-14 membered heteroaryl, wherein the point of attachment of the 3-14 membered heterocyclyl or 5-14 membered heteroaryl group is on a nitrogen atom;each instance of RB10 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each instance of RB11 is, independently, selected from hydrogen, —OH, —ORB10, —N(RB12)2, —CN, —C(═O)RB10, —C(═O)N(RB12)2, —CO2RB10, —SO2RB10, —C(═NRB12)ORB10, —C(═NRB12)N(RB12)2, —SO2N(RB12)2, —SO2RB12, —SO2ORB12, —SORB10, —C(═S)N(RB12)2, —C(═O)SRB12, —C(═S)SRB12, —P(═O)2RB10, —P(═O)2(RB10)2, —P(═O)2N(RB12)2, —P(═O)(NRB12)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB11 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; andeach instance of RB12 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB12 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring. 9. The compound of claim 8, wherein RE is selected from halogen, —OH, —ORB10, —ON(RB11)2, —N(RB11)2, —N(ORB12)RB12, —SH, —SRB10, —SSRB12, —Si(RB10)3, —OSi(RB10)3, —P(RB12)2, —P(RB12)3, —OP(RB12)2, —OP(RB12)3, 3-14 membered heterocyclyl and 5-14 membered heteroaryl, wherein the point of attachment of the 3-14 membered heterocyclyl or 5-14 membered heteroaryl group is on a nitrogen atom. 10. The compound of claim 9, wherein RE is selected from halogen, —ORB10 and —N(RB11)2. 11. The compound of claim 1, wherein RC is C3-10 alkyl. 12. The compound of claim 1, wherein RC is C3-10 carbocyclyl. 13. The compound of claim 1, wherein RA is C6-14 aryl or 5-14 membered heteroaryl, and RB is C6-14 aryl. 14. The compound of claim 13, wherein RA is C6-14 aryl and RB is C6-14 aryl. 15. The compound of claim 13, wherein RA is 5-14 membered heteroaryl and RB is C6-14 aryl. 16. The compound of claim 1, wherein the compound is of the formula (II): or a pharmaceutically acceptable form thereof;wherein each group W—R1, W—R2, W—R3, W—R4, and W—R5 independently represents either a nitrogen atom (N) or C—R1, C—R2, C—R3, C—R4, or C—R5, respectively; andwherein R1, R2, R3, R4 and R5 are, independently, selected from the group consisting of hydrogen, halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —ON(RA2)2, —N(RA2)2, —N(ORA3)RA3, —SH, —SRA1, —SSRA3, —C(═O)RA1, —CO2H, —CHO, —C(ORA3)2, —CO2RA1, —OC(═O)RA1, —OCO2RA1, —C(═O)N(RA2)2, —OC(═O)N(RA2)2, —NRA2C(═O)RA1, —NRA2CO2RA1, —NRA2C(═O)N(RA2)2, —C(═NRA2)ORA1, —OC(═NRA2)RA1, —OC(═NRA2)ORA1, —C(═NRA2)N(RA2)2, —OC(═NRA2)N(RA2)2, —NRA2C(═NRA2)N(RA2)2, —C(═O)NRA2SO2RA1, —NRA2SO2RA1, —SO2N(RA2)2, —SO2RA1, —SO2ORA1, —OSO2RA1, —S(═O)RA1, —OS(═O)RA1, —Si(RA1)3, —OSi(RA1)3—C(═S)N(RA2)2, —C(═O)SRA1, —C(═S)SRA1, —SC(═S)SRA1, —P(═O)2RA1, —OP(═O)2RA1, —P(═O)(RA1)2, —OP(═O)(RA1)2, —OP(═O)(ORA3)2, —P(═O)2N(RA2)2, —OP(═O)2N(RA2)2, —P(═O)(NRA2)2, —OP(═O)(NRA2)2, —NRA2P(═O)(ORA3)2, —NRA2P(═O)(NRA2)2, —P(RA3)2, —P(RA3)3, —OP(RA3)2, —OP(RA3)3, —B(ORA3)2, or —BRA1(ORA3), C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl; or one or more of R1 and R2, R2 and R3, R3 and R4 or R4 and R5 are joined to form a C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl ring;each instance of RA1 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each instance of RA2 is, independently, selected from hydrogen, —OH, —ORA1, —N(RA3)2, —CN, —C(═O)RA1, —C(═O)N(RA3)2, —CO2RA1, —SO2RA1, —C(═NRA3)ORA1, —C(═NRA3)N(RA3)2, —SO2N(RA3)2, —SO2RA3, —SO2ORA3, —SORA1, —C(═S)N(RA3)2, —C(═O)SRA3, —C(═S)SRA3, —P(═O)2RA1, —P(═O)(RA1)2, —P(═O)2N(RA3)2, —P(═O)(NRA3)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RA2 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; andeach instance of RA3 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RA3 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;wherein each group W—R6, W—R7, W—R8, W—R9, and W—R10 independently represents either a nitrogen atom (N) or C—R6, C—R7, C—R8, C—R9, or C—R10, respectively;R6, R7, R8, R9 and R10 are, independently, selected from the group consisting of hydrogen, halogen, —CN, —NO2, —N3, —SO2H, —SO3H, —OH, —ORB1, —ON(RB2)2, —N(RB2)2, —N(ORB3)RB3, —SH, —SRB1, —SSRB3, —C(═O)RB1, —CO2H, —CHO, —C(ORB3)2, —CO2RB1, —OC(═O)RB1, —OCO2RB1, —C(═O)N(RB2)2, —OC(═O)N(RB2)2, —NRB2C(═O)RB1, —NRB2CO2RB1, —NRB2C(═O)N(RB2)2, —C(═NRB2)ORB1, —OC(═NRB2)RB1, —OC(═NRB2)ORB1, —C(═NRB2)N(RB2)2, —OC(═NRB2)N(RB2)2, —NRB2C(═NRB2)N(RB2)2, —C(═O)NRB2SO2RB1, —NRB2SO2RB1, —SO2N(RB2)2, —SO2RB1, —SO2ORB1, —OSO2RB1, —S(═O)RB1, —OS(═O)RB1, —Si(RB1)3, —OSi(RB1)3—C(═S)N(RB2)2, —C(═O)SRB1, —C(═S)SRB1, —SC(S)SRB1, —P(═O)2RB1, —OP(═O)2RB1, —P(═O)(RB1)2, —OP(═O)(RB1)2, —OP(═O)(ORB3)2, —P(═O)2N(RB2)2, —OP(═O)2N(RB)2, —P(═O)(NRB2)2, —OP(═O)(NRB2)2, —NRB2P(═O)(ORB3)2, —NRB2P(═O)(NRB2)2, —P(RB3)2, —P(RB3)3, —OP(RB3)2, —OP(RB3)3, —B(ORB3)2, —BRB1(ORB3), C1-10 alkyl, C1-10-perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, 5-14 membered heteroaryl, -L-RD and —RE; or one or more of R6 and R7, R7 and R8, R8 and R9 or R9 and R10 are joined to form a C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl or 5-14 membered heteroaryl ring; or R10 and RC are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;wherein at least one of R6, R7, R8, R9, and R10 is the group -L-RD;each instance of RB1 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each instance of RB2 is, independently, selected from hydrogen, —OH, —ORB1, —N(RB3)2, —CN, —C(═O)RB1, —C(═O)N(RB3)2, —CO2RB1, —SO2RB1, —C(═NRB3)ORB1, —C(═NRB3)N(RB3)2, —SO2N(RB3)2, —SO2RB3, —SO2ORB3, —SORB1, —C(═S)N(RB3)2, —C(═O)SRB3, —C(═S)SRB3, —P(═O)2RB1, —P(═O)(RB1)2, —P(═O)2N(RB3)2, —P(═O)(NRB3)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB2 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;each instance of RB3 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB3 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;L is a covalent bond or a divalent C1-10 hydrocarbon chain, wherein one, two or three methylene units of L are optionally and independently replaced with one or more —O—, —S—, —NRB8-, —(C═NRB8)—, —C(═O)—, —C(═S)—, —S(═O)—, —S(═O)2—, divalent carbocyclyl, divalent heterocyclyl, divalent aryl or divalent heteroaryl group; andwherein RD is selected from —N3, —SO2H, —SO3H, —C(═O)RB7, —CO2H, —CHO, —C(ORB9)2, —CO2RB7, —OC(═O)RB7, —OCO2RB7, —C(═O)N(RB8)2, —OC(═O)N(RB8)2, —NRB8C(═O)RB7, —NRB8CO2RB7, —NRB8C(═O)N(RB8)2, —C(═NRB8)ORB7, —OC(═NRB8)RB7, —OC(═NRB8)ORB7, —C(═NRB8)N(RB8)2, —OC(═NRB8)N(RB8)2, —NRB8C(═NRB8)N(RB8)2, —C(═O)NRB8SO2RB7, —NRB8SO2RB7, —SO2N(RB8)2, —SO2RB7, —SO2ORB7, —OSO2RB7, —S(═O)RB7, —OS═ORB7, —C(═S)N(RB8)2, —C(═O)SRB7, —C(═S)SRB7, —SC(═S)SRB7, —P(═O)2RB7, —OP(═O)2RB7, —P(═O)(RB7)2, —OP(═O)(RB7)2, —OP(═O)(ORB9)2, —P(═O)2N(RB8)2, —OP(═O)2N(RB8)2, —P(═O)(NRB8)2, —OP(═O)(NRB8)2, —NRB8P(═O)(ORB9)—NRB8P(═O)(NRB8)2, —B(ORB9)2, —BRB7(ORB9) and tetrazolyl;each instance of RB7 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each instance of RB8 is, independently, selected from hydrogen, —OH, —ORB7, —N(RB9)2, —CN, —C═ORB7, —C(═O)N(RB9)2, —CO2RB7, —SO2RB7, —C(═NRB9)ORB7, —C(═NRB9)N(RB9)2, —SO2N(RB9)2, —SO2RB9, —SO2ORB9, —SORB7, —C(═S)N(RB9)2, —C(═O)SRB9, —C(═S)SRB9, —P(═O)2RB7, —P(═O)(RB7)2, —P(═O)2N(RB9)2, —P(═O)(NRB9)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB8 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; andeach instance of RB9 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB9 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;RE is selected from halogen, —OH, —ORB10, —ON(RB11)2, —N(RB11), —N(ORB12)RB12, —SH, —SRB10, —SSRB12, —OC(═O)RB10, —OCO2RB10, —OC(═O)N(RB11)2, —NRB11C(═O)RB10, —NRB11CO2RB10, —NRB11C(═O)N(RB11)2, —OC(═NRB11)RB10, —OC(═NRB11)ORB10, —OC(═NRB11)N(RB11)2, —NRB11C(═NRB11)N(RB11)2, —NRB11SO2RB10, —OSO2RB10, —OS(═O)RB10, —Si(RB10)3, —OSi(RB10)3, —SC(S)SRB10, —OP(═O)2RB10, —OP(═O)(RB10)2, —OP(═O)(ORB12)2, —OP(═O)2N(RB11)2, —OP(═O)(NRB11)2, —NRB11P(═O)(ORB12)2, —NRB11P(═O)(NRB11)2, —P(RB12)2, —P(RB12)3, —OP(RB12)2, —OP(RB12)3, 3-14 membered heterocyclyl and 5-14 membered heteroaryl, wherein the point of attachment of the 3-14 membered heterocyclyl or 5-14 membered heteroaryl group is on a nitrogen atom;each instance of RB10 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl;each instance of RB11 is, independently, selected from hydrogen, —OH, —ORB10, —N(RB12)2, —CN, —C(═O)RB10, —C(═O)N(RB12)2, —CO2RB10, —SO2RB10, —C(═NRB12)ORB10, —C(═NRB12)N(RB12)2, —SO2N(RB12)2, —SO2RB12, —SO2ORB12, —SORB10, —C(═S)N(RB12)2, —C(═O)SRR12, —C(═S)SRB12, —P(═O)2RB10, —P(═O)(RB10)2, —P(═O)2N(RB12)2, —P(═O)(NRB12)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB11 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;each instance of RB12 is, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RB12 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring;RC is selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, with the proviso that RC is not —CH3. 17. The compound of claim 16, wherein at least one of R6, R7, R8, R9 and R10 is the group —RE. 18. A pharmaceutical composition comprising a compound of formula (I): or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient;wherein:RA is selected from C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl and 5-14 membered heteroaryl;RB is selected from C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl and 5-14 membered heteroaryl;RC is selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl. 19. A pharmaceutical composition comprising at least one compound of formula (I) according to claim 1, or a pharmaceutically acceptable form thereof; and at least one pharmaceutically acceptable excipient. 20. The compound of claim 16, wherein the group of the formula is a group of formula 21. The compound of claim 20, where the group of formula is a group of formula 22. The compound of claim 21, wherein one of R1 and R5 is halogen, —CN, —ORA1, —N(RA2)2, —CO2H, —CO2RA1, —C(═O)N(RA2)2, —SO2RA1, C1-10 alkyl, C2-10 alkynyl, 3-14 membered heterocyclyl, and C6-14 aryl, and the other of R1 and R5 is halogen, —CN, —ORA1, —N(RA2)2, —CO2H, —CO2RA1, —C(═O)N(RA2)2, —SO2RA1, C1-10 alkyl, C2-10 alkynyl, 3-14 membered heterocyclyl, and C6-14 aryl. 23. The compound of claim 22, wherein one of R1 and R5 is halogen, —ORA1, C1-10 alkyl, or —C(═O)N(RA2)2, and the other of R1 and R5 is halogen, —ORA1, C1-10 alkyl, or —C(═O)N(RA2)2. 24. The compound of claim 23, wherein each of R1 and R5) is independently halogen. 25. The compound of claim 24, wherein each of R1 and R5 is independently selected from fluoro and chloro. 26. The compound of claim 25, wherein each of R1 and R3 is independently fluoro. 27. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable form thereof. 28. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable form thereof. 29. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable form thereof. 30. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable form thereof. 31. The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable form thereof. 32. The pharmaceutical composition of claim 19 wherein the compound is: or a pharmaceutically acceptable form thereof. 33. The pharmaceutical composition of claim 19, wherein the compound is: or a pharmaceutically acceptable form thereof. 34. The pharmaceutical composition of claim 19, wherein the compound is: or a pharmaceutically acceptable form thereof. 35. The pharmaceutical composition of claim 19, wherein the compound is: or a pharmaceutically acceptable form thereof.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Kuhajda Francis P. ; Pasternack Gary R. ; Townsend Craig A. ; Mani Neelakandha S., Inhibition of fatty acid synthase as a means to reduce adipocyte mass.
Hadvary Paul (Biel-Benken CHX) Hochuli Erich (Arisdorf CHX) Kupfer Ernst (Basel CHX) Lengsfeld Hans (Reinach CHX) Weibel Ernst K. (Pratteln CHX), Leucine derivatives.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Newell,Martha Karen; Villobos Menuey,Elizabeth; Newell,Evan, Methods for treating human proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.